UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~December 239, 2020

OWC Pharmaceutical Research Corp.

(Exact Name of Registrant as Specified in its Charter)

Commission File No.: 0-54856

Delaware		98-0573566
(State of Incorporation)		(I.R.S. Employer Identification No.)

2 Ben Gurion Street, Ramat Gan, Israel		4514760
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, including area code: 972 (0) 3-758-2657

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock		OWCP		OTCPQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 5 8.0701 ~~Submission~~Other ~~of Matters to a Vote of Security Holders~~Events.

On ~~September~~December 2110, 2020, ~~the~~One ~~OWC~~World ~~Pharmaceutical~~Cannabis ~~Research Corp~~Ltd. (~~the~~ “~~Company~~OWC-Israel”), ~~held~~an ~~the~~Israeli ~~continuation~~subsidiary of aOWC ~~special~~Pharmaceutical ~~meeting of~~Research ~~stockholders that was scheduled for August 31~~Corp., filed ~~2020~~a ~~and~~petition ~~was~~under ~~adjourned~~the toInsolvency ~~September 14, 2020~~ and toRehabilitation ~~September 21~~Law, ~~2020~~2018 ~~(the “Meeting”)~~in ~~for stockholders to vote on~~ the ~~following~~Israeli ~~proposals:~~Haifa ~~(i)~~District toCourt. ~~authorize~~As ~~the~~stated ~~Company’s~~in ~~Board of Directors to effect one reverse stock split of~~ the ~~Company’s outstanding Common Stock~~petition, ~~$0.00001 par value per share, at any ratio~~ ~~between 1~~OWC-~~for-10~~Israel ~~and~~is ~~1-for-20~~insolvent at ~~such time as~~ the ~~Company’s~~present ~~Board~~time ofand ~~Directors~~met ~~shall~~the ~~determine,~~conditions inrequired ~~its~~under ~~sole~~Israeli ~~discretion, before~~law ~~seven~~for ~~(7)~~submitting ~~days~~a ~~after~~petition ~~the~~to ~~closing of~~ the ~~Meeting (“Proposal No~~ court. ~~1”);~~OWC-Israel ~~(ii)~~stated tothat ~~amend~~it ~~the~~believes ~~Company’s~~that ~~Certificate of~~there ~~Incorporation,~~were asno ~~amended~~alternatives to ~~increase~~filing the ~~number~~petition ~~of the Company’s authorized shares of Common Stock from 500,000,000 shares to 2,500,000,000 shares (“Proposal No. 2”);~~ and ~~(iii)~~having tothe ~~approve~~court ~~one~~find ora ~~more adjournments to the Meeting, if~~suitable ~~necessary~~solution orfor ~~appropriate, to permit further solicitation of proxies if there are not sufficient votes at~~ the ~~time~~benefit of ~~the~~its ~~Meeting cast in favor of Proposals No~~creditors. ~~1 and/or No. 2 (“Proposal No. 3”).~~

As of August 4, 2020, (the “Record Date”) for the Meeting, there were 497,498,338 shares of the Company’s Common Stock issued and outstanding and entitled to vote with one vote per share on each proposal, 381 shares of the Company’s Series A Preferred Stock, which entitled the holders thereof to an aggregate of 24,825,167 votes and 43,675 shares of the Company’s Series B Preferred Stock issued and outstanding and were entitled to an aggregate of 43,675,000 votes.

In order to conduct the business of the Meeting, the Company required the presence, in person or by proxy, of a quorum consisting of a majority of the outstanding shares of stock entitled to vote as of the Record Date. Quorum was present at the Meeting, and the Company’s stockholders approved a further adjournment of the Meeting to October 28, 2020 (the “Adjournment Date”), to allow additional time for stockholders to vote and seek approval for Proposals No. 1 and 2.

The vote results for Proposal 3, the only proposal that had an effect at the Meeting were as follows:

Votes For		Votes Against		Abstentions
155,880,704		110,805,564		19,550,190

The Company will amend this Current Report on Form 8-K to report the results of the vote on Proposals 1 and 2 following the Adjournment Date.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OWC PHARMACEUTICAL RESEARCH CORP.

	By:	/s/ Ziv Turner
	Name:	Ziv Turner
	Title:	Chief Executive Officer

Dated: ~~September~~December 2514, 2020

Filing Compare · OWC Pharmaceutical Research Corp.